A recent study tracked a total of 434 new active substances (NASs) approved by Health Canada between 1995 and 2010. The NASs were then compared to see whether a difference in safety existed between those that had gone through Health Canada’s standard 300-day review period vs. the 180-day priority process. Drugs streamed into Health Canada’s accelerated review process are 15% more likely to be withdrawn from the market or to earn a serious safety warning.
Archives of Internal Medicine, October 2012